пропозиції роботи
Aleksandra Misiorowska
Business Leader | Marketing Strategies, Commercial Lead | Pharma, Life sciences |
Paris,
Île-de-France,
France
Dołącz do GoldenLine i obejrzyj pełny profil tej użytkowniczki
Zobacz pełny profil
Umiejętności
Biotechnologia
Zarządzanie Marką
Analiza biznesowa
Rozwój działalności
Strategia biznesowa
Kardiologia
Przewlekłe Choroby
Badania kliniczne
Komercjalizacja
Wywiad konkurencji
Cross-functional Team Leadership
Cukrzyca
Rozwój leków
Rynki wschodzące
Endokrynologia
Globalny Marketing
Ekonomika zdrowia
Choroby zakaźne
Rozwój międzynarodowy
Marketing Międzynarodowy
Lifesciences
Dostęp do rynku
Analiza rynku
Marketing Leadership
Strategia marketingowa
przemówienia motywacyjne
Przemysł farmaceutyczny
Sprzedaż leków
Farmaceutyka
wprowadzanie produktu
Zarządzanie cyklem życia produktu
Zarządzanie produktem
Zdrowie publiczne
Readiness
Regulacje
Efektywność Sprzedaży
Zarządzanie Sprzedażą
Planowanie strategiczne
Myślenie strategiczne
Strategia
Języki
polski
ojczysty
angielski
biegły
francuski
biegły
włoski
podstawowy
Doświadczenie zawodowe
Senior Director, Head of Marketing and Sales Operations
StallergenesGreer
Promoted to lead Strategic Marketing and Sales Operations of Allergy Immunotherapy portfolio ( >€150M; Europe & International)
• Prepares global launch of Actair – first lunch since decades in STAGR ( launch 2021)
• Provided 5Y Strategic Growth Initiatives Plan aiming to double revenue and improve EBIDTA acting as a sponsor for several initiatives including entering animal health, LCM, RWE program
• Repositioned and re-branded main brands driving differentiation and ms% gain despite constant stock-outs
• Restructured Marketing & Sales Operation Team driving efficiency and productivity (reduction of HC from 11 to 7; 60% of the team new hires; reduction of Operational expenses by 70%)
• Prepares global launch of Actair – first lunch since decades in STAGR ( launch 2021)
• Provided 5Y Strategic Growth Initiatives Plan aiming to double revenue and improve EBIDTA acting as a sponsor for several initiatives including entering animal health, LCM, RWE program
• Repositioned and re-branded main brands driving differentiation and ms% gain despite constant stock-outs
• Restructured Marketing & Sales Operation Team driving efficiency and productivity (reduction of HC from 11 to 7; 60% of the team new hires; reduction of Operational expenses by 70%)
Associate Director, Access & Product Management
Medicines for Malaria Venture
Medicines for Malaria Venture (MMV) an international non-profit organization, is the leading public-private product development partnership (PDP) in a field of the antimalarial drugs.
My Key area of responsibility:
• Lead chemoprevention portfolio strategy and non-profit strategic marketing
• Support the development of the market-driven TPPs and product development strategies
• Drive access to health initiatives helping malaria endemic countries and NGOs to access innovative and affordable new antimalarials
• Guide pharmaceutical partners with integrated development, market access and launch strategies and commercialization planning to facilitate introduction of the new antimalarials into public market in malaria endemic countries in Africa and Asia
• Manage day-to-day operations with public health bodies, NGOs and academia to reinforce evidence-based adoption of new products
PUBLIC SPEAKING:
• 6th MIM PAN African Malaria Conference, Durban (2013):
presentation title: „Increasing access to medicines for Seasonal Malaria Chemoprevention – role of MMV”
My Key area of responsibility:
• Lead chemoprevention portfolio strategy and non-profit strategic marketing
• Support the development of the market-driven TPPs and product development strategies
• Drive access to health initiatives helping malaria endemic countries and NGOs to access innovative and affordable new antimalarials
• Guide pharmaceutical partners with integrated development, market access and launch strategies and commercialization planning to facilitate introduction of the new antimalarials into public market in malaria endemic countries in Africa and Asia
• Manage day-to-day operations with public health bodies, NGOs and academia to reinforce evidence-based adoption of new products
PUBLIC SPEAKING:
• 6th MIM PAN African Malaria Conference, Durban (2013):
presentation title: „Increasing access to medicines for Seasonal Malaria Chemoprevention – role of MMV”
General Manager
StallergenesGreer
Assigned to take an interim leadership over Czech.Rep / Slovakia affiliate ( >€8M) with an objective of preparing for the last promotional cycle, executing the year closure and building budget and plan for 2020
Senior Director, Head of Marketing Excellence, EU/INT
StallergenesGreer
Recruited to upgrade/re-build marketing capabilities and drive business excellence of Allergy Immunotherapy portfolio (>€150M; Europe & International)
• Implemented new yearly Brand Planning & Budgeting process
• Implemented new SFE initiatives setting Sales Force Effectiveness basics - increasing call coverage and frequency vs plan from 60% to 80% and revising targeting and segmentation across Europe
• Set up and led new governance and performance reporting for EU/INT Region Commercial Operations including lead on quarterly business review and GM
• Implemented new yearly Brand Planning & Budgeting process
• Implemented new SFE initiatives setting Sales Force Effectiveness basics - increasing call coverage and frequency vs plan from 60% to 80% and revising targeting and segmentation across Europe
• Set up and led new governance and performance reporting for EU/INT Region Commercial Operations including lead on quarterly business review and GM
Marketing Team Leader
Led marketing/commercial of Cardiovascular and Women’s Health portfolios ( >€250M; 9 Asian markets including China)
• Set up 4 new products introductions (branded generic launches)
• Secured organizational readiness and built commercial implementation plan for new clinical data
• Drove “above the pill” regional initiative and insight driven culture
• Set up 4 new products introductions (branded generic launches)
• Secured organizational readiness and built commercial implementation plan for new clinical data
• Drove “above the pill” regional initiative and insight driven culture
Marketing Manager Asia Area
Led Diabetes portfolio marketing/commercial; products in a pre-launch and launch phase ( >€120M; 9 Asian markets including India)
• Delivered the fastest in the antidiabetics market sales growth increasing market share and gaining rank in the total non-insulin antidiabetic market ( from #7 to #6 diabetes company in sales)
• Drove Forxiga launch roll-out and post launch market penetration- performance on pair with best launches within AZ markets Global and benchmarked against the best diabetes launch ever
• Prepared launch of once-weekly GLP1 including: injectable capabilities building
• Drove partner and second brand strategies for mature products across multiple markets
• Involvement in Patients Centricity global project
• Delivered the fastest in the antidiabetics market sales growth increasing market share and gaining rank in the total non-insulin antidiabetic market ( from #7 to #6 diabetes company in sales)
• Drove Forxiga launch roll-out and post launch market penetration- performance on pair with best launches within AZ markets Global and benchmarked against the best diabetes launch ever
• Prepared launch of once-weekly GLP1 including: injectable capabilities building
• Drove partner and second brand strategies for mature products across multiple markets
• Involvement in Patients Centricity global project
Associate Business Director - Emerging Markets, Diabetes Franchise
Promoted to lead Diabetes Franchise marketing & sales across Emerging Markets
(BRIC+ AsiaPac, LATAM, Near & Middle East, Africa), ( >€250M )
Delivered double digit sales growth over the period, exceeding sales target & reaching costs savings target in 2011 and consolidated market leadership position.
• Defined Diabetes Franchise Emerging Markets strategy and business plans
• Developed commercial strategy for entering diabetes market in China
• Managed roll-out lunch of Glucophage® LCM and launch of the new product (vildagliptin) in the partnership with Novartis in LATAM (co-marketing)
• Successfully implemented new collaboration model HQ/Regional Hubs/Countries; worked closely with regional hubs (Singapore, Dubai, Mexico) on the execution of the franchise strategy; supporting and guiding key marketing activities, driving LCM roll-out, identifying and prioritizing market opportunities
PUBLIC SPEAKING:
• Eyeforpharma Conference “Commercial excellence in Emerging Markets”, Berlin (2011)
presentation title: “Give the second life to the mature brand in Emerging Markets”
(BRIC+ AsiaPac, LATAM, Near & Middle East, Africa), ( >€250M )
Delivered double digit sales growth over the period, exceeding sales target & reaching costs savings target in 2011 and consolidated market leadership position.
• Defined Diabetes Franchise Emerging Markets strategy and business plans
• Developed commercial strategy for entering diabetes market in China
• Managed roll-out lunch of Glucophage® LCM and launch of the new product (vildagliptin) in the partnership with Novartis in LATAM (co-marketing)
• Successfully implemented new collaboration model HQ/Regional Hubs/Countries; worked closely with regional hubs (Singapore, Dubai, Mexico) on the execution of the franchise strategy; supporting and guiding key marketing activities, driving LCM roll-out, identifying and prioritizing market opportunities
PUBLIC SPEAKING:
• Eyeforpharma Conference “Commercial excellence in Emerging Markets”, Berlin (2011)
presentation title: “Give the second life to the mature brand in Emerging Markets”
Global Strategic Marketing Manager, Diabetes Franchise
Promoted to co-lead Diabetes Franchise Global Strategic Marketing across Mature & Emerging Markets ( >€300M).
• Rejuvenated global mature Diabetes Portfolio and delivered sales double digit growth:
• Supported development and implementation of the global strategic guidance and global brands plans
• Developed and led implementation of the new branding, communication plan and implementation support, seeking efficiency via marketing processes improvement
• Rejuvenated global mature Diabetes Portfolio and delivered sales double digit growth:
• Supported development and implementation of the global strategic guidance and global brands plans
• Developed and led implementation of the new branding, communication plan and implementation support, seeking efficiency via marketing processes improvement
Product Manager Diabetes & Thyroid Franchise
• Established strong company footprint and reputation within the diabetes field.
- defined and executed pre-launch and launch strategy for diabetes product, including organization shaping, registration, market access and pricing strategies.
• Maximized revenue and leadership market position of the mature thyroid portfolio:
- 1st Merck International Award for Brand Promotion
- Merck ENDO & CMC Marketing Excellence Award
- defined and executed pre-launch and launch strategy for diabetes product, including organization shaping, registration, market access and pricing strategies.
• Maximized revenue and leadership market position of the mature thyroid portfolio:
- 1st Merck International Award for Brand Promotion
- Merck ENDO & CMC Marketing Excellence Award
Medical Representative
Therapeutic areas including: Cardiovascular, Endocrinology, Women’s Health
Szkolenia i kursy
Kursy:
- Charted Institute of Marketing
- Charted Institute of Marketing
Edukacja
Philosophy, magisterskie
Cardinal Stefan Wyszynski University in Warsaw
Specjalizacje
Sprzedaż
Farmacja/Medycyna
